Satellos Bioscience (TSE:MSCL)
TSX:MSCL
Want to see TSE:MSCL full AI Analyst Report?
Top Page
Satellos Bioscience
(TSX:MSCL)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$10.00
▼(-16.04% Downside)
Action:Reiterated
Date:05/19/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and continued cash burn), partially offset by a debt-free balance sheet. Technicals are mildly negative with limited momentum, and valuation metrics provide limited support due to negative earnings and no indicated dividend.
Positive Factors
Debt-free balance sheet
Having no debt materially reduces financial leverage risk and preserves flexibility for an early-stage biotech. It lowers fixed obligations, improving the company’s ability to fund R&D through equity raises or collaborations without near-term refinancing pressure, a durable strength.
Negative Factors
Pre-revenue operations
Being pre-revenue means no product sales to offset costs, leaving commercial validation and sustainable cash generation unproven. Over a multi-month horizon this sustains binary outcome risk tied to clinical progress and partnerships rather than recurring operational cash flows.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Having no debt materially reduces financial leverage risk and preserves flexibility for an early-stage biotech. It lowers fixed obligations, improving the company’s ability to fund R&D through equity raises or collaborations without near-term refinancing pressure, a durable strength.
Read all positive factors
Satellos Bioscience (MSCL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$210.40M
Dividend YieldN/A
Average Volume (3M)178.54K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue GrowthN/A
EPS Growth6.61%
CountryCA
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.11
Shares Outstanding20,831,190
10 Day Avg. Volume239,110
30 Day Avg. Volume178,539
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$28.57Price Target Upside139.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.88
Revenue Forecast (FY)N/A
Satellos Bioscience Business Overview & Revenue Model
Company Description
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system whic...
How the Company Makes Money
null...
Satellos Bioscience Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -6.13K | -5.09K | -20.00K | -8.82M | -3.73M | -119.92K |
| EBITDA | -29.97M | -26.92M | -28.08M | -15.71M | -8.09M | -4.60M |
| Net Income | -28.45M | -25.31M | -28.10M | -15.89M | -11.32M | -15.51M |
Balance Sheet | ||||||
| Total Assets | 75.28M | 31.83M | 73.02M | 44.30M | 6.20M | 12.59M |
| Cash, Cash Equivalents and Short-Term Investments | 69.96M | 27.66M | 69.85M | 39.59M | 1.92M | 4.87M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.57M | 4.10M | 5.16M | 3.62M | 2.83M | 2.10M |
| Stockholders Equity | 70.71M | 27.73M | 67.86M | 40.67M | 3.37M | 10.48M |
Cash Flow | ||||||
| Free Cash Flow | -25.78M | -24.02M | -24.98M | -14.52M | -5.79M | -5.04M |
| Operating Cash Flow | -25.77M | -24.01M | -24.98M | -14.50M | -5.78M | -5.03M |
| Investing Cash Flow | -42.25M | -9.58M | 6.34M | -17.54M | -3.00K | 1.74M |
| Financing Cash Flow | 53.29M | 2.28M | 53.48M | 51.03M | 2.77M | 7.45M |
Satellos Bioscience Technical Analysis
Positive
11.91
Price Trends
9.80
Positive
11.90
Negative
10.09
Positive
Market Momentum
-0.18
Negative
51.40
Neutral
64.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MSCL, the sentiment is Positive. The current price of 11.91 is above the 20-day moving average (MA) of 10.03, above the 50-day MA of 9.80, and above the 200-day MA of 10.09, indicating a bullish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 51.40 is Neutral, neither overbought nor oversold. The STOCH value of 64.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MSCL.
Satellos Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$210.40M | -1.76 | -51.42% | ― | ― | 6.61% | |
46 Neutral | C$121.06M | -29.67 | -66.34% | ― | ― | 69.04% | |
42 Neutral | C$29.21M | -2.73 | -103.51% | ― | ― | 57.98% | |
41 Neutral | C$30.23M | -10.91 | 72.34% | ― | ― | 26.83% |
* Healthcare Sector Average
TSE:MSCL
Satellos Bioscience
10.10
2.90
40.28%
TSE:ARCH
Arch Biopartners
0.45
-1.36
-75.28%
TSE:MDNA
Medicenna Therapeutics Corp
0.43
-0.53
-55.73%
TSE:HBP
Helix BioPharma
1.59
0.66
72.28%
TSE:METX
ME Therapeutics Holdings, Inc.
1.72
-8.54
-83.24%
TSE:ONCO
Onco-Innovations Ltd.
1.47
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.